COCH Stock Forecast & Price Target

Envoy Medical is attractive because its lead Esteem FI-AMEI already provides a commercial revenue base, while the investigational Acclaim CI could unlock a much larger hearing-loss market through a differentiated fully implanted design that avoids external components and may improve daily use and adoption. The fundamentals are strengthening as the company submitted the first of four PMA modules in June 2026, advanced the U.S. pivotal trial to 56 implanted patients with the final implant in March 2026, and reported 12-month Stage 1 data showing CNC scores improving to 53.2% from 39.2% at six months and 15.2% pre-implantation, with 9 of 10 participants responding positively and no protocol-defined serious adverse events. Although 2Q26 revenue was only $51K and the net loss was $7.3M, the improving clinical profile and continued regulatory progress support a positive long-term outlook.

Envoy Medical is facing a fragile liquidity profile, with just $19.7M of cash at the end of June 2026 and $5.5M of operating cash outflow in 2Q26, suggesting limited financial flexibility. The company’s reliance on possible warrant exercises for up to $48M of gross proceeds adds uncertainty, while its need to regain NASDAQ minimum bid-price compliance by November 16, 2026 underscores ongoing market-pressure risk. With revenue concentrated in the Esteem FI-AMEI and replacement components and management expecting additional capital within the next 12 months absent warrant exercises, dilution and financing risk remain major fundamental headwinds.